Dr. Agarwal on the Advantages of Docetaxel in Prostate Cancer

Neeraj Agarwal, MD
Published: Friday, Jan 12, 2018



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).

One of the advantages of docetaxel chemotherapy is the dosaging schedule, says Agarwal. It is a short schedule lasting about 4 and a half months, consisting of 6 cycles of docetaxel every 6 weeks. The other option is abiraterone acetate (Zytiga) with prednisone, which needs to be continued indefinitely for as long as the patient is benefitting.

As for the side effect profile, as docetaxel is a chemotherapy there is neuropathy and myelosuppression, but patients often need to come to the hospital for infusions, which is inconvenient compared to an oral therapy.


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the advantages and disadvantages of choosing docetaxel as a therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).

One of the advantages of docetaxel chemotherapy is the dosaging schedule, says Agarwal. It is a short schedule lasting about 4 and a half months, consisting of 6 cycles of docetaxel every 6 weeks. The other option is abiraterone acetate (Zytiga) with prednisone, which needs to be continued indefinitely for as long as the patient is benefitting.

As for the side effect profile, as docetaxel is a chemotherapy there is neuropathy and myelosuppression, but patients often need to come to the hospital for infusions, which is inconvenient compared to an oral therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x